Neurotoxicity Syndromes

"Neurotoxicity Syndromes" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Neurologic disorders caused by exposure to toxic substances through ingestion, injection, cutaneous application, or other method. This includes conditions caused by biologic, chemical, and pharmaceutical agents.

Descriptor ID	D020258
MeSH Number(s)	C10.720 C25.723.705
Concept/Terms	Neurotoxicity Syndromes Neurotoxicity Syndromes Neurotoxicity Syndrome Syndrome, Neurotoxicity Syndromes, Neurotoxicity Neurotoxin Disorders Neurotoxin Disorder Neurotoxic Disorders Neurotoxic Disorder Neurotoxin Diseases Neurotoxin Disease Poisoning, Nervous System Nervous System Poisonings Poisonings, Nervous System Nervous System Poisoning Encephalopathy, Toxic Encephalopathy, Toxic Encephalopathies, Toxic Toxic Encephalopathies Toxic Encephalopathy Toxic Encephalitis Toxic Encephalitis Encephalitides, Toxic Encephalitis, Toxic Toxic Encephalitides

Below are MeSH descriptors whose meaning is more general than "Neurotoxicity Syndromes".

Diseases [C]
Nervous System Diseases [C10]
Neurotoxicity Syndromes [C10.720]
Chemically-Induced Disorders [C25]
Poisoning [C25.723]
Neurotoxicity Syndromes [C25.723.705]

Below are MeSH descriptors whose meaning is related to "Neurotoxicity Syndromes".

Below are MeSH descriptors whose meaning is more specific than "Neurotoxicity Syndromes".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Neurotoxicity Syndromes" by people in this website by year, and whether "Neurotoxicity Syndromes" was a major or minor topic of these publications.

Bar chart showing 18 publications over 13 distinct years, with a maximum of 2 publications in 2009 and 2010 and 2016 and 2020 and 2022

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2000	1	0	1
2006	1	0	1
2007	1	0	1
2008	0	1	1
2009	2	0	2
2010	2	0	2
2011	1	0	1
2013	1	0	1
2016	1	1	2
2018	1	0	1
2020	2	0	2
2021	0	1	1
2022	2	0	2

Below are the most recent publications written about "Neurotoxicity Syndromes" by people in Profiles.

Jones DK, Eckhardt CA, Sun H, Tesh RA, Malik P, Quadri S, Firme MS, van Sleuwen M, Jain A, Fan Z, Jing J, Ge W, Nascimento FA, Sheikh IS, Jacobson C, Frigault M, Kimchi EY, Cash SS, Lee JW, Dietrich J, Westover MB. EEG-based grading of immune effector cell-associated neurotoxicity syndrome. Sci Rep. 2022 11 21; 12(1):20011.

View in: PubMed
Amidi Y, Eckhardt CA, Quadri SA, Malik P, Firme MS, Jones DK, Jain A, Danish HH, Rubin DB, Jacobson CA, Cash SS, Lee JW, Dietrich J, Westover MB. Forecasting immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor t-cell therapy. J Immunother Cancer. 2022 11; 10(11).

View in: PubMed
van de Donk NWCJ, Usmani SZ, Yong K. CAR T-cell therapy for multiple myeloma: state of the art and prospects. Lancet Haematol. 2021 Jun; 8(6):e446-e461.

View in: PubMed
Lerner DP, Tadevosyan A, Burns JD. Toxin-Induced Subacute Encephalopathy. Neurol Clin. 2020 11; 38(4):799-824.

View in: PubMed
Xue J, Zhang L, Xie X, Gao Y, Jiang L, Wang J, Wang Y, Gao R, Yu J, Xiao H. Prenatal bisphenol A exposure contributes to Tau pathology: Potential roles of CDK5/GSK3?/PP2A axis in BPA-induced neurotoxicity. Toxicology. 2020 05 30; 438:152442.

View in: PubMed
Santomasso BD, Park JH, Salloum D, Riviere I, Flynn J, Mead E, Halton E, Wang X, Senechal B, Purdon T, Cross JR, Liu H, Vachha B, Chen X, DeAngelis LM, Li D, Bernal Y, Gonen M, Wendel HG, Sadelain M, Brentjens RJ. Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia. Cancer Discov. 2018 08; 8(8):958-971.

View in: PubMed
Ferreri AJ, Cwynarski K, Pulczynski E, Ponzoni M, Deckert M, Politi LS, Torri V, Fox CP, Ros?e PL, Schorb E, Ambrosetti A, Roth A, Hemmaway C, Ferrari A, Linton KM, Rud? R, Binder M, Pukrop T, Balzarotti M, Fabbri A, Johnson P, G?rl?v JS, Hess G, Panse J, Pisani F, Tucci A, Stilgenbauer S, Hertenstein B, Keller U, Krause SW, Levis A, Schmoll HJ, Cavalli F, Finke J, Reni M, Zucca E, Illerhaus G. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematol. 2016 May; 3(5):e217-27.

View in: PubMed
Lee DK, Youk H, Kim H, Kim OH, Go J, Kim TH, Cha K, Lee KH, Hwang SO, Cha YS. Initial Serum Ammonia as a Predictor of Neurologic Complications in Patients with Acute Glufosinate Poisoning. Yonsei Med J. 2016 Jan; 57(1):254-9.

View in: PubMed
Jackson DA, Cotter BV, Merchant RC, Babu KM, Baird JR, Nirenberg T, Linakis JG. Behavioral and physiologic adverse effects in adolescent and young adult emergency department patients reporting use of energy drinks and caffeine. Clin Toxicol (Phila). 2013 Aug; 51(7):557-65.

View in: PubMed
Shen EY, Ali SF, Meyer JS. Chronic administration of THC prevents the behavioral effects of intermittent adolescent MDMA administration and attenuates MDMA-induced hyperthermia and neurotoxicity in rats. Neuropharmacology. 2011 Dec; 61(8):1183-92.

View in: PubMed

People

Explore

Similar Concepts

Top Journals